Discounted Cash Flow Rating

Strong Buy

Return on Equity Rating

Sell

Debt to Equity Rating

Strong Buy

Price to Earnings Rating

Strong Buy

Analyst Rating

Strong Buy

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Buy

Standard Deviation

Neutral

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Strong Buy

Wall Street Data Solutions Rating

Buy

A

Alimera Sciences, Inc. (ALIM)

Pharmaceutical Preparations

https://www.alimerasciences.com

Alimera Sciences Inc is a commercial-stage pharmaceutical company developing and commercializing ILUVIEN for the treatment of diabetic macular edema (DME), a leading cause of blindness, and outside the U.S. for non-infectious uveitis affecting the posterior segment of the eye (NIU-PS). ILUVIEN is a sustained-release intravitreal implant that enables patients to maintain vision longer, and importantly, with fewer injections. The company commercializes ILUVIEN in the U.S., Europe, China and the Middle East.

6310 TOWN SQUARE, SUITE 400
ALPHARETTA, GA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

04/22/2010

Market Cap

303,697,688

Shares Outstanding

52,420,000

Weighted SO

52,416,841

Total Employees

N/A

Upcoming Earnings

08/08/2024

Similar Tickers

SHPH --.--%

LFCR --.--%

MNK --.--%

DERM --.--%

LSDI --.--%

ADMP --.--%

ORGO --.--%

CYTH --.--%

ATNX --.--%

Beta

1.2840

Last Div

0.0000

Range

2.606-5.65

Chg

0.0043

Avg Vol

415866

Mkt Cap

303697688

Exch

NASDAQ

Country

US

Phone

678 990 5740

DCF Diff

4.8561

DCF

7.4661

Div Yield

0.0000

P/S

3.0467

EV Multiple

184.3402

P/FV

7.8296

Div Yield %

0.0000

P/E

-20.6637

PEG

-1.6128

Payout

-0.0857

Current Ratio

2.7930

Quick Ratio

2.6189

Cash Ratio

0.5475

DSO

135.7715

DIO

55.3443

Op Cycle

191.1158

DPO

163.5179

CCC

27.5978

Gross Margin

0.7714

Op Margin

0.0085

Pretax Margin

-0.1487

Net Margin

-0.1474

Eff Tax Rate

0.0082

ROA

-0.0977

ROE

-0.3370

ROCE

0.0065

NI/EBT

0.9918

EBT/EBIT

-17.4125

EBIT/Rev

0.0085

Debt Ratio

0.4670

D/E

1.8104

LT Debt/Cap

0.6426

Total Debt/Cap

0.6442

Int Coverage

0.2602

CF/Debt

-0.0797

Equity Multi

3.8769

Rec Turnover

2.6883

Pay Turnover

2.2322

Inv Turnover

6.5951

FA Turnover

30.4462

Asset Turnover

0.6629

OCF/Share

-0.1029

FCF/Share

-0.1070

Cash/Share

0.1997

OCF/Sales

-0.0561

FCF/OCF

1.0395

CF Coverage

-0.0797

ST Coverage

-11.4204

CapEx Coverage

-25.3213

Div&CapEx Cov

-3.7811

P/BV

7.8296

P/B

7.8296

P/S

3.0467

P/E

-20.6637

P/FCF

-52.2086

P/OCF

-54.2699

P/CF

-54.2699

PEG

-1.6128

P/S

3.0467

EV Multiple

184.3402

P/FV

7.8296

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Dec 12, 07:30 Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire Inc. Nov 08, 16:30 Alimera Appoints Maggie A. Pax to Its Board of Directors

Revenue Product Segmentation